Stéphane Debono
Fondateur chez HalioDxinvest SAS
Profil
Stéphane Debono is the founder of QIAGEN Marseille SA, which was founded in 1999.
He held the position of Chief Operating Officer & Director from 2012 to 2014.
Mr. Debono is also the founder of HalioDxinvest SAS.
Currently, he is a Director at Ipsogen, Inc. Mr. Debono's former positions include Director at Pharmaxon SAS from 2009 to 2012, Principal at Beckman Coulter, Inc. and ImmunoTechnology Corp., and Chief Technology Officer at BioInformatics LLC.
Mr. Debono received his undergraduate degree from Centrale Marseille.
Postes actifs de Stéphane Debono
| Sociétés | Poste | Début |
|---|---|---|
Ipsogen, Inc.
 Ipsogen, Inc. Medical/Nursing ServicesHealth Services Part of QIAGEN NV, Ipsogen, Inc. is a company that develops and markets molecular diagnostic tests for leukemia and breast cancer. The company is based in Stamford, CT. The company was founded by Vincent Fert. | Directeur/Membre du Conseil | - |
HalioDxinvest SAS
 HalioDxinvest SAS BiotechnologyHealth Technology HalioDxinvest SAS develops and researches biotechnology products. The company was incorporated on October 17, 2014 and is headquartered in Marseille, France. | Fondateur | - |
Anciens postes connus de Stéphane Debono
| Sociétés | Poste | Fin |
|---|---|---|
| QIAGEN MARSEILLE | Fondateur | 07/12/2014 |
Pharmaxon SAS
 Pharmaxon SAS Pharmaceuticals: MajorHealth Technology Despite recent advances in diagnostics, imaging, medical devices and surgical procedures, there has been limited progress in pharmacological treatments for a number of neurological and neuro-oncological pathologies. For pathologies like central and peripheral nervous system injuries, degenerative diseases and tumours of the nervous system, the unmet medical needs are countless and there is growing expectation from the medical community, the patients and their relatives to benefit from clinically proven solutions in the future that will save and/or improve the lives of many. The limited efficacy of approved therapies for some of these pathologies and the orphan nature of others has prompted the urgent need for new researches and therapeutic strategies. At Pharmaxon, as the pioneers of a novel pharmacological approach based on cell mobility modulation, the firm is developing the future 'control keys' for improving the nervous system's endogenous regeneration, modulating neuronal networks plasticity, and inhibiting the processes which underlie tumour cell proliferation and migration. This is obtained by modulating the activity of specific adhesion molecules implicated in cell migration, cell adhesion and cell growth. Based on such a targeted strategy, Pharmaxon is opening up new avenues for the medical management of some serious, poorly-treated, neurology and neuro-oncology pathologies. To date, this has led to three R&D programs which have reached proof-of-principle, confirming the therapeutic potential of this innovative approach, in clinic stage by 2008. | Directeur/Membre du Conseil | 18/12/2012 |
BioInformatics LLC
 BioInformatics LLC Miscellaneous Commercial ServicesCommercial Services BioInformatics LLC provides market research services. The firm focuses on scientific research to diagnostics and therapeutics. The firm specializes in assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customers brand loyalty, and evaluating brand strength and positioning. The company was founded by William T. Kelly, Justin Dudash and Karen L. Blaine in 1994 and is headquartered in Arlington, VA. | Directeur Technique/Scientifique/R&D | - |
| ImmunoTechnology Corp. | Corporate Officer/Principal | - |
Beckman Coulter, Inc.
 Beckman Coulter, Inc. Medical SpecialtiesHealth Technology Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA. | Corporate Officer/Principal | - |
Formation de Stéphane Debono
| Centrale Marseille | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
QIAGEN Marseille SA
 QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France. | Commercial Services |
Beckman Coulter, Inc.
Beckman Coulter, Inc. Medical SpecialtiesHealth Technology Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA. | Health Technology |
| ImmunoTechnology Corp. | Retail Trade |
BioInformatics LLC
BioInformatics LLC Miscellaneous Commercial ServicesCommercial Services BioInformatics LLC provides market research services. The firm focuses on scientific research to diagnostics and therapeutics. The firm specializes in assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customers brand loyalty, and evaluating brand strength and positioning. The company was founded by William T. Kelly, Justin Dudash and Karen L. Blaine in 1994 and is headquartered in Arlington, VA. | Commercial Services |
Pharmaxon SAS
Pharmaxon SAS Pharmaceuticals: MajorHealth Technology Despite recent advances in diagnostics, imaging, medical devices and surgical procedures, there has been limited progress in pharmacological treatments for a number of neurological and neuro-oncological pathologies. For pathologies like central and peripheral nervous system injuries, degenerative diseases and tumours of the nervous system, the unmet medical needs are countless and there is growing expectation from the medical community, the patients and their relatives to benefit from clinically proven solutions in the future that will save and/or improve the lives of many. The limited efficacy of approved therapies for some of these pathologies and the orphan nature of others has prompted the urgent need for new researches and therapeutic strategies. At Pharmaxon, as the pioneers of a novel pharmacological approach based on cell mobility modulation, the firm is developing the future 'control keys' for improving the nervous system's endogenous regeneration, modulating neuronal networks plasticity, and inhibiting the processes which underlie tumour cell proliferation and migration. This is obtained by modulating the activity of specific adhesion molecules implicated in cell migration, cell adhesion and cell growth. Based on such a targeted strategy, Pharmaxon is opening up new avenues for the medical management of some serious, poorly-treated, neurology and neuro-oncology pathologies. To date, this has led to three R&D programs which have reached proof-of-principle, confirming the therapeutic potential of this innovative approach, in clinic stage by 2008. | Health Technology |
Ipsogen, Inc.
Ipsogen, Inc. Medical/Nursing ServicesHealth Services Part of QIAGEN NV, Ipsogen, Inc. is a company that develops and markets molecular diagnostic tests for leukemia and breast cancer. The company is based in Stamford, CT. The company was founded by Vincent Fert. | Health Services |
HalioDxinvest SAS
HalioDxinvest SAS BiotechnologyHealth Technology HalioDxinvest SAS develops and researches biotechnology products. The company was incorporated on October 17, 2014 and is headquartered in Marseille, France. | Health Technology |
